I tend to agree with you but it is bizarre that the best Pharma did not make an offer just based on the fact that the stock trades at cash. Even a $10.00 offer would have only cost them 500mil.
The patents need to be worth something, the cash is cash and Asia has to have some value. Plus this is a potentially life saving drug and new rules are in place. This could be a blockbuster and even if approved with or without a label it is suicide to market this without big Pharma as a partner at the very least.
My wife works at PFE and does trials and even a quick look she saw liver toxicity issues and gave it a 50 50 chance.
Very surprising that the best they could do was a reverse merge with a private company. 2 CEO's gone this year. The street doesn't think much of this management.
Of course, that can change on a dime with approvals.
Axis Technologies Group and Carbonis Forge Ahead with New Digital Carbon Credit Technology • AXTG • Apr 24, 2024 3:00 AM
North Bay Resources Announces Successful Equipment Test at Bishop Gold Mill, Inyo County, California • NBRI • Apr 23, 2024 9:41 AM
Epazz, Inc.: CryObo, Inc. solar Bitcoin operations will issue tokens • EPAZ • Apr 23, 2024 9:20 AM
Avant Technologies Launches Advanced AI Supercomputing Network and Expansive Data Solutions • AVAI • Apr 23, 2024 8:00 AM
BestGrowthStocks.com Issues Comprehensive Analysis of Triller Merger with AGBA Group Holding Limited • AGBA • Apr 22, 2024 1:00 PM
Cannabix Technologies to Present Marijuana Breathalyzer Technology at International Association for Chemical Testing (IACT) Conference in California • BLO • Apr 22, 2024 8:49 AM